Companies / BOC Sciences / Daratumumab
BOC Sciences

Daratumumab | BOC Sciences

Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.